TAILIEUCHUNG - Ebook Top 300 pharmacy drug cards: Part 2

(BQ) The best and easiest way to learn essential information about the top 300 drugs. Every card includes: Generic and common name, class, dosage forms, approved dose and indications, off-label use, contraindications, adverse reactions, drug interactions,. | Drug Interactions: Isosorbide Mononitrate Typical Agents CYP3A4/5 inducers CYP3A4/5 inhibitors Phosphodiesterase inhibitors (erectile dys unction medications) Mechanism Increased metabolism o isosorbide mononitrate decreases isosorbide e cacy Decreased metabolism o isosorbide mononitrate increases risk o isosorbide mononitrate toxicity Excessive hypotension Clinical Management Monitor or toxicity and consider dose increases o isosorbide mononitrate Monitor or e cacy and consider dose decreases o isosorbide mononitrate Concurrent use contraindicated; separate sildena l and vardena l rom nitrates by 24 h; tardena l rom nitrates by 48 h Adverse Reactions: Isosorbide Mononitrate Common (>10%) Dizziness, headache Less Common (1-10%) Bradycardia, f ushing, hypotension, nausea, orthostatic hypotension, tachycardia, vomiting Rare but Serious (10%) Application site reaction with foam Less Common (1-10%) Dry skin, burning, stinging at site of application Rare but Serious (90% hepatic and primari y via g ucuronide conjugation Elimination Rena e imination is 55-60% (5% unchanged) and 50% in eces, with a ha - i e o 5-8 h Pharmacogenetics None known Black Box Warnings None Medication Sa ety Issues: Labetalol Suf xes No Tall Man Letters No L Do Not Crush No High Alert Yes (IV on y) 148 Con used Names Betaxo o , amoTRIgine, Lipitor Beers Criteria No Drug Interactions: Labetalol Typical Agents A pha-/Beta-agonists A pha1-b ockers, entany Beta-b ockers, amiodarone, dronedarone Antidiabetic drugs Ca cium channe b ockers Mechanism Labeta o may enhance the vasopressor e ect o a pha-/beta-agonist Additive orthostatic hypotension Increased risk o bradycardia, heart b ock, sinus arrest Decreased g ycemic contro Increased risk o hypotension and/or bradycardia and AV b ock Clinical Management Avoid concurrent use or monitor BP Avoid concurrent use or monitor BP Avoid concurrent use in patients with sick sinus syndrome or AV b ock Monitor b ood g ucose eve s Avoid .

• Y khoa - Dược
• Top 300 pharmacy drug cards
• Pharmacy drug cards
• Generic and common name
• Dosage forms
• Approved dose and indications
• Off label use
• Adverse reactions
• Direct oral anticoagulant
• Adverse reaction
• DOAC induced gastrointestinal
• FDAs Adverse Event Reporting System
• Japanese Adverse Drug Event Report
• BMC Pharmacology and Toxicology
• Adverse drug reactions
• Antiepileptic drug
• Severe adverse reactions
• Psychiatric ADRs
• BMC Pediatrics
• Spontaneous reports
• ADR database
• Adverse drug reactions older adults
• Side effects
• drug reactions
• Veterinary adverse
• medicinal products
• Pharmacovigilance
• Practical veterinary
• Veterinary pharmacovigilance
• OTC drugs
• Drug safety
• Spontaneous reporting
• KPC outbreak
• Extensively drug resistant
• Multidrug resistant
• Drug drug interactions
• Drug protein interactions
• Synergistic drug drug interactions
• Modified drug administration guidelines
• Clinical manifestations
• Trigger tool
• Quality assurance
• Emergency room
• Chronic kidney disease
• Survival rate
• Conservative management
• BMC Veterinary Research
• Food allergy
• Oral food challenge
• Oral provocation
• Cutaneous adverse food reactions
• Sufficiently hydrolyzed protein sources
• BMC Cancer
• Medication literacy
• Skin adverse drug reactions
• Non small cell lung cancer
• Targeted therapy
• Adverse drug events
• Space time
• ADE rate clustering
• Hospital admissions
• Length of stay
• Non β lactams antibiotics
• Arylamine N acetyltransferases
• Genetic polymorphism
• Ankylosing spondylitis
• Nervous system medications
• Nervous system mediations
• EudraVigilance database
• Cancer patients
• Quality of life
• Adverse events
• Mortality risk prediction model
• Laboratory variables
• Creatine phosphokinase
• Myotoxicity induced
• Mitochondrial myopathies
• Perceived adverse effect
• Antiretroviral therapy
• Self report ADRs
• Antiretroviral treatment
• Adverse drug reaction
• Medical records systems
• Although adverse drug reactions
• Primary Care Clinical Informatics Unit
• Medical coding
• National Health Service
• International Classification of Disease
• Healthcare professional
• ADR reporting play vital role
• Regional Pharmacovigilance Centres
• Observational study
• Drug interactions
• Emergency department
• During admission
• South African children’s hospitals